Literature DB >> 23007407

A prospective study of circulating adipokine levels and risk of multiple myeloma.

Jonathan N Hofmann1, Linda M Liao, Michael N Pollak, Ye Wang, Ruth M Pfeiffer, Dalsu Baris, Gabriella Andreotti, Qing Lan, Ola Landgren, Nathaniel Rothman, Mark P Purdue.   

Abstract

It has been hypothesized that the observed excess risk of multiple myeloma (MM) among obese persons could be the result of altered circulating levels of adipokines, polypeptide hormones with pro- and anti-inflammatory properties secreted by adipose tissue. We investigated whether circulating levels of leptin, total adiponectin, and high molecular weight adiponectin are associated with subsequent MM risk among 174 MM patients and 348 controls within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Inverse associations with MM were observed for total adiponectin (highest quartile vs lowest: odds ratio = 0.49; 95% CI = 0.26-0.93, P(trend) = .03) and high molecular weight adiponectin (0.44; 0.23-0.85, P(trend) = .01). These associations remained after restricting to MM patients diagnosed ∼ 8 years or more after blood collection. Leptin levels were not associated with MM risk. The results of this study, to our knowledge the first prospective investigation of circulating adipokines and MM, suggest that adiponectin may play an important role in obesity-related myelomagenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23007407      PMCID: PMC3507148          DOI: 10.1182/blood-2012-06-438606

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  Adipocytokines: mediators linking adipose tissue, inflammation and immunity.

Authors:  Herbert Tilg; Alexander R Moschen
Journal:  Nat Rev Immunol       Date:  2006-09-22       Impact factor: 53.106

Review 2.  Multiple myeloma: a review of the epidemiologic literature.

Authors:  Dominik D Alexander; Pamela J Mink; Hans-Olov Adami; Philip Cole; Jack S Mandel; Martin M Oken; Dimitrios Trichopoulos
Journal:  Int J Cancer       Date:  2007       Impact factor: 7.396

3.  Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial.

Authors:  R B Hayes; D Reding; W Kopp; A F Subar; N Bhat; N Rothman; N Caporaso; R G Ziegler; C C Johnson; J L Weissfeld; R N Hoover; P Hartge; C Palace; J K Gohagan
Journal:  Control Clin Trials       Date:  2000-12

4.  Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes.

Authors:  Kolapo M Ajuwon; Michael E Spurlock
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-12-16       Impact factor: 3.619

5.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

6.  Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study.

Authors:  Maria Dalamaga; Konstantinos Karmaniolas; Anna Panagiotou; Alex Hsi; John Chamberland; Cleanthi Dimas; Antigoni Lekka; Christos S Mantzoros
Journal:  Cancer Causes Control       Date:  2008-09-24       Impact factor: 2.506

7.  Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells.

Authors:  Ya-Wei Qiang; Lei Yao; Giovanna Tosato; Stuart Rudikoff
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

8.  The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Authors:  Anne Catherine Sprynski; Dirk Hose; Laurent Caillot; Thierry Réme; John D Shaughnessy; Bart Barlogie; Anja Seckinger; Jérôme Moreaux; Michael Hundemer; Michel Jourdan; Tobias Meissner; Anna Jauch; Karène Mahtouk; Alboukadel Kassambara; Uta Bertsch; Jean François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2009-02-18       Impact factor: 22.113

Review 9.  Obesity and the role of adipose tissue in inflammation and metabolism.

Authors:  Andrew S Greenberg; Martin S Obin
Journal:  Am J Clin Nutr       Date:  2006-02       Impact factor: 7.045

Review 10.  Survival and proliferation factors of normal and malignant plasma cells.

Authors:  Bernard Klein; Karin Tarte; Michel Jourdan; Karene Mathouk; Jerome Moreaux; Eric Jourdan; Eric Legouffe; John De Vos; Jean François Rossi
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

View more
  26 in total

1.  Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study.

Authors:  Su-Hsin Chang; Suhong Luo; Theodore S Thomas; Katiuscia K O'Brian; Graham A Colditz; Nils P Carlsson; Kenneth R Carson
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

2.  Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals.

Authors:  Jonathan N Hofmann; Brenda M Birmann; Lauren R Teras; Ruth M Pfeiffer; Ye Wang; Demetrius Albanes; Dalsu Baris; Graham A Colditz; Anneclaire J De Roos; Graham G Giles; H Dean Hosgood; Qing Lan; Ola Landgren; Linda M Liao; Nathaniel Rothman; Stephanie J Weinstein; Michael N Pollak; Marian L Neuhouser; Mark P Purdue
Journal:  Cancer Res       Date:  2016-02-26       Impact factor: 12.701

3.  Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies.

Authors:  Lauren R Teras; Cari M Kitahara; Brenda M Birmann; Patricia A Hartge; Sophia S Wang; Kim Robien; Alpa V Patel; Hans-Olov Adami; Elisabete Weiderpass; Graham G Giles; Pramil N Singh; Michael Alavanja; Laura E Beane Freeman; Leslie Bernstein; Julie E Buring; Graham A Colditz; Gary E Fraser; Susan M Gapstur; J Michael Gaziano; Edward Giovannucci; Jonathan N Hofmann; Martha S Linet; Gila Neta; Yikyung Park; Ulrike Peters; Philip S Rosenberg; Catherine Schairer; Howard D Sesso; Meir J Stampfer; Kala Visvanathan; Emily White; Alicja Wolk; Anne Zeleniuch-Jacquotte; Amy Berrington de González; Mark P Purdue
Journal:  Br J Haematol       Date:  2014-05-23       Impact factor: 6.998

4.  Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study.

Authors:  Marianna Thordardottir; Ebba K Lindqvist; Sigrun H Lund; Rene Costello; Debra Burton; Neha Korde; Sham Mailankody; Gudny Eiriksdottir; Lenore J Launer; Vilmundur Gudnason; Tamara B Harris; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Blood Adv       Date:  2017-11-01

5.  Obesity and neoplasms of lymphohematopoietic cells.

Authors:  Marshall A Lichtman
Journal:  Blood Adv       Date:  2016-11-22

Review 6.  Multiple Myeloma and Bone: The Fatal Interaction.

Authors:  Silvia Marino; G David Roodman
Journal:  Cold Spring Harb Perspect Med       Date:  2018-08-01       Impact factor: 6.915

7.  Abdominal adipose tissue in MGUS and multiple myeloma.

Authors:  Joyce Veld; Elizabeth K O'Donnell; Michaela R Reagan; Andrew J Yee; Martin Torriani; Clifford J Rosen; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2016-06-25       Impact factor: 2.199

Review 8.  Adipose, Bone, and Myeloma: Contributions from the Microenvironment.

Authors:  Michelle M McDonald; Heather Fairfield; Carolyne Falank; Michaela R Reagan
Journal:  Calcif Tissue Int       Date:  2016-06-24       Impact factor: 4.333

Review 9.  Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?

Authors:  Adi J Klil-Drori; Laurent Azoulay; Michael N Pollak
Journal:  Nat Rev Clin Oncol       Date:  2016-08-09       Impact factor: 66.675

Review 10.  Leptin and its receptor in hematologic malignancies.

Authors:  Tian-Jie Han; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.